Hepion Pharmaceuticals, Inc. (OTCPK: HEPA)
Health Care · Pharmaceuticals · US
$0.08
-7.32% today · -10.0% 1Y
Hepion Pharmaceuticals, Inc. (OTCPK: HEPA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $7.96M and employs 2 people.
Over the last twelve months the share price has lost 10.0%, trading between 0.03 and 0.12.
Tweenvest scores Hepion Pharmaceuticals, Inc. across four factors: quality 35/100, value 89/100. Its strongest factor is value.
HEPA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $7.96M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.25
- Dividend yield
- —
- Beta (5Y)
- 1.75
- 52-week high
- $0.12
- 52-week low
- $0.03
- Avg volume (3M)
- —
- Shares outstanding
- 98.22M
- Employees
- 2
- Next earnings
- —
About Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
- ISIN
- US4268974015
- Founded
- 2013
- Listed since
- Feb 10, 2014
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Greenway Greenhouse Cannabis CorporationCNSX: GWAY | $8.43M | CA$0.09 | +12.50% |
| Incanthera plcOFEX: INC | $8.23M | £0.04 | +9.33% |
| TFF Pharmaceuticals, Inc.MUN: 0K30 | $8.20M | €— | — |
| Annexin Pharmaceuticals AB (publ)OM: ANNX | $7.96M | Skr9.16 | +1.55% |
| Pila Pharma AB (publ)OM: PILA | $7.92M | Skr1.66 | -4.60% |
| CNS Pharmaceuticals, Inc.NasdaqCM: CNSP | $7.78M | $5.35 | +0.47% |
| Revive Therapeutics Ltd.CNSX: RVV | $7.64M | CA$0.03 | +25.00% |
| Zenith Drugs LimitedNSEI: ZENITHDRUG | $7.49M | Rs42.05 | -1.75% |
Figures last refreshed Oct 4, 2026.